A Comparison of One Versus Two Doses of Influenza Vaccine in Children 5-8 Years of Age

Influenza Clinical Trial

Official title:

A Comparison of One Versus Two Doses of Influenza Vaccine in Children Aged 5-8 Years of Age Receiving Influenza Vaccine for the First Time

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00158665
• Other study ID #: CDC Protocol 4258
• Secondary ID: VSD contract #20
• Status: Completed
• Phase: N/A
• First received: September 8, 2005
• Last updated: October 11, 2017
• Start date: August 2004
• Est. completion date: December 2004

Study information

• Verified date: October 2017
• Source: Kaiser Permanente
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study was to find out if children 5 through 8 years of age who are getting influenza vaccine for the first time should get one or two doses.

Description:

Currently, two doses of influenza vaccine are recommended for children younger than 9 years receiving influenza vaccine for the first time. While the scientific support for 2 doses of vaccine in infants and toddlers is sound, the need for 2 doses of vaccine for adequate immunogenicity in older children is less certain. If the immunogenicity of a one-dose vaccine regimen is comparable to a two-dose regimen, then one dose would be preferable for reasons of safety, practicality and economics, and would reduce a major barrier to vaccination in this injection-adverse age group. This study compared the immunogenicity and reactogenicity of one versus two doses of influenza vaccine in children aged 5 to 8 years old receiving influenza vaccine for the first time. All children enrolled in the study received two doses of vaccine, and the immune response after one dose of vaccine was compared to the immune response after two doses of vaccine.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 280
• Est. completion date: December 2004
• Est. primary completion date: December 2004
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 5 Years to 8 Years

Eligibility

Inclusion Criteria:

• Immunocompetent children who are at least 5 and no more than 8 years of age on the date of the first vaccination.

• Parents able to give informed consent and child available for all study visits.

• Family able to understand and comply with planned study procedures.

• Family must have telephone accessibility.

Exclusion Criteria:

• Previous receipt of influenza vaccine of any kind (shot or nasal spray).

• Active cancer or blood system abnormalities such as leukemia.

• Immunocompromising illnesses or current receipt of immunosuppressive agents

• Allergy to eggs or egg protein, or to gentamicin (an antibiotic that is present in trace amounts in the vaccine).

• Any acute or chronic condition that (in the opinion of the investigator) would render vaccination unsafe or would interfere with the evaluation of responses.

Temporary Exclusion Criteria:

Acute disease, defined as the presence of moderate or severe illness with or without fever, at the time of enrollment. Influenza vaccine may be administered to children with minor illnesses, such as diarrhea, mild upper respiratory infection and low-grade febrile illness with an oral temperature <100.4 F.

Related Conditions & MeSH terms

• Influenza
• Influenza, Human

Intervention

Biological:
• 2 0.5 ml doses of '04-05 Trivalent Influenza Vaccine
2 0.5 ml doses of '04-05 Trivalent Influenza Vaccine

Locations

Country	Name	City	State
United States	Group Health Research Institute	Seattle	Washington

Sponsors (2)

Lead Sponsor	Collaborator
Kaiser Permanente	Centers for Disease Control and Prevention

Country where clinical trial is conducted

United States, 

References & Publications (1)

Neuzil KM, Jackson LA, Nelson J, Klimov A, Cox N, Bridges CB, Dunn J, DeStefano F, Shay D. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children. J Infect Dis. 2006 Oct 15;1 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Comparison of antibody response after 1 dose of influenza vaccine with that after 2 doses of influenza vaccine.		Blood samples were obtained at 3 time points, before dose 1 of vaccine, 4 weeks after receipt of dose 1 and before dose 2, and 4 weeks after dose 2 of vaccine.
Secondary	To describe and compare the safety profile after 1 and 2 doses of vaccine.		Study diaries were kept from the day of vaccination daily for the 4 days after vaccination.